Japan
· Delayed Price · Currency is JPY Carna Biosciences Company Description
Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan.
Its products include kinase proteins, substrates, Luciferase PPI stable cell lines, kinase assay kits, peptide substrate, mobility shifty assay, and lipid kinase panels.
The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection assays.
It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials.
The company has collaborations with Sumitomo Pharma, Gilead Sciences. Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan.
| Country | Japan |
| Founded | 2003 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 63 |
| CEO | Kohichiro Yoshino |
Contact Details
Address: BMA, 1-5-5 Minatojima-Minamimachi Kobe, 650-0047 Japan | |
| Phone | 81 78 302 7039 |
| Website | carnabio.com |
Stock Details
| Ticker Symbol | 4572 |
| Exchange | Tokyo Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | JPY |
| ISIN Number | JP3220550002 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Kohichiro Yoshino | Chief Executive Officer |
| Emi Yamamoto | Chief Financial Officer |